Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Biotech Stocks on Investors' Radar -- Halozyme Therapeutics, Cara Therapeutics, PDL BioPharma, and Arena Pharma

PR Newswire April 13, 2017

The Legal Cannabis Market Expected to Witness Wider Adoption

PR Newswire April 12, 2017

The Global Legal Cannabis Market Gains Momentum

PR Newswire April 7, 2017

Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire April 5, 2017

The Growth of Legal Cannabis Industry Sales

PR Newswire March 31, 2017

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  March 31, 2017

Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock

GlobeNewswire March 30, 2017

Pain-Reducing Combination Therapies Proving Successful Thanks to Innovative, Specialty Pharma Players

PR Newswire March 30, 2017

20 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  March 30, 2017

Cara Therapeutics Announces Proposed Offering of Common Stock

GlobeNewswire March 29, 2017

Cara Therapeutics to Webcast Presentation at the 16th Annual Needham Healthcare Conference

GlobeNewswire March 28, 2017

20 Biggest Mid-Day Gainers For Tuesday

Benzinga.com  March 28, 2017

Cara Therapeutics' 15% Surge, Explained

Benzinga.com  March 28, 2017

Cara Therapeutics Announces Positive Top-Line Data From Part A of Phase 2/3 Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus

GlobeNewswire March 28, 2017

The Legal Cannabis Market Developments in 2017

PR Newswire March 27, 2017

Watch These 7 Huge Put Purchases In Friday Trade

Benzinga.com  March 24, 2017

Legal Cannabis Market Contributes to Tax Revenues

PR Newswire March 20, 2017

5 Biotech Companies Set for Major Breakouts in 2017

PR Newswire March 17, 2017

Legal Cannabis Sales Projected to Grow

PR Newswire March 15, 2017

Cara Therapeutics to Present at March Medical Meetings

GlobeNewswire March 13, 2017